Researcher

James Kirkland

Last updated Sun May 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)· 2 min read

Background

James Kirkland (with long-time collaborator Tamir Tchkonia) leads the Robert and Arlene Kogod Center on Aging at Mayo Clinic. A geriatrician by training, he has bridged basic senescence biology and human trials — one of the few figures who has carried a discovery from cell culture to first-in-human pilot.

Key contributions

SCAP framework

Identification of senescent-cell anti-apoptotic pathways (SCAPs) as the molecular vulnerability senolytics exploit. Different senescent cell types depend on different SCAPs (BCL-xL family, PI3K/AKT, ephrin-B-dependent, p53/p21), motivating combination senolytic strategies that hit multiple pathways at once.

Dasatinib + quercetin (D+Q)

Discovery and characterisation of the D+Q combination as the first senolytic protocol, with dasatinib targeting tyrosine-kinase-dependent survival pathways and quercetin targeting BCL-xL and PI3K. The protocol clears senescent cells across multiple tissues in aged mice and improves healthspan endpoints even when started late in life.

First-in-human senolytic trials

Led first-in-human pilots in:

Idiopathic pulmonary fibrosis (3-week D+Q pilot showed improved 6-minute walk distance).
Diabetic kidney disease (reduced adipose-tissue senescent-cell burden, lower inflammatory cytokines).
Frailty in older adults (ongoing trial network).

Translational Geroscience Network

Founded the multi-site Translational Geroscience Network to run geroscience-style trials across major US academic centres, providing infrastructure for the field that previously didn’t exist outside disease-specific trial networks.

Influence

Founded a translational discipline

Kirkland’s lab essentially founded the senolytic field as a translational discipline. The SCAP framework guides ongoing senolytic-drug discovery and clinical-trial design. His careful staged approach — pre-clinical to first-in-human pilot to larger trials — is now the template other geroscience translational efforts follow.

Affiliations & disclosures

Mayo Clinic. Patents on senolytic-protocol applications licensed to multiple companies; financial disclosures appear with publications.

References

Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518–536 (2020).